Not Just What, But When: Neoadjuvant Pembrolizumab in Melanoma Not Just What, But When: Neoadjuvant Pembrolizumab in Melanoma

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news